- Home
- WTRG vs INSM Comparison
WTRG vs INSM Comparison
Compare WTRG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTRG
- INSM
- Stock Information
- Founded
- WTRG 1901
- INSM 1988
- Country
- WTRG United States
- INSM United States
- Employees
- WTRG N/A
- INSM N/A
- Industry
- WTRG Water Supply
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- WTRG Utilities
- INSM Health Care
- Exchange
- WTRG Nasdaq
- INSM Nasdaq
- Market Cap
- WTRG 11.1B
- INSM 12.6B
- IPO Year
- WTRG N/A
- INSM 2000
- Fundamental
- Price
- WTRG $40.76
- INSM $65.08
- Analyst Decision
- WTRG Strong Buy
- INSM Strong Buy
- Analyst Count
- WTRG 6
- INSM 16
- Target Price
- WTRG $43.50
- INSM $95.36
- AVG Volume (30 Days)
- WTRG 1.3M
- INSM 2.5M
- Earning Date
- WTRG 05-12-2025
- INSM 05-08-2025
- Dividend Yield
- WTRG 3.19%
- INSM N/A
- EPS Growth
- WTRG 16.67
- INSM N/A
- EPS
- WTRG 2.17
- INSM N/A
- Revenue
- WTRG $2,086,113,000.00
- INSM $381,030,000.00
- Revenue This Year
- WTRG $14.33
- INSM $30.36
- Revenue Next Year
- WTRG $6.96
- INSM $115.55
- P/E Ratio
- WTRG $18.79
- INSM N/A
- Revenue Growth
- WTRG 1.57
- INSM 20.77
- 52 Week Low
- WTRG $33.18
- INSM $21.92
- 52 Week High
- WTRG $41.78
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- WTRG 55.33
- INSM 35.80
- Support Level
- WTRG $40.24
- INSM $63.81
- Resistance Level
- WTRG $41.60
- INSM $73.39
- Average True Range (ATR)
- WTRG 0.77
- INSM 2.53
- MACD
- WTRG -0.05
- INSM -0.38
- Stochastic Oscillator
- WTRG 58.82
- INSM 13.26
About WTRG Essential Utilities Inc.
Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.